The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus–Related Head and Neck Cancer
Abstract
BACKGROUND: Human papillomavirus (HPV) is the most identifiable cause of head and neck squamous cell cancer (HNSCC). Compared with HPV-negative HNSCC, HPV-positive HNSCC presents at an advanced stage but with significantly better survival. We created a syngeneic mouse model of HPV-positive and HPV-negative HNSCC by transforming mouse primary tonsil epithelial cells with either HPV oncogenes or a nonantigenic RNA interference strategy that affects similar oncogenic pathways. OBJECTIVES: To examine the effect of radiation therapy on HPV-positive and HPV-negative tumors in immune-competent and immune-incompetent mice and to examine responses in human cancer cell lines. DESIGN: Prospective in vivo murine model. MAIN OUTCOME MEASURES: Survival and tumor growth. RESULTS: For human and murine transformed cell lines, HPV-positive cells were more resistant to radiation and cisplatin therapy compared with HPV-negative cells. In vivo, HPV-positive tumors were more sensitive to radiation, with complete clearance at 20 Gy, compared with their HPV-negative counterparts, which showed persistent growth. Cisplatin in vivo cleared HPV-positive tumors but not HPV-negative tumors. However, neither radiation or cisplatin therapy cured immune-incompetent mice. Adoptive transfer of wild-type immune cells into immune-incompetent mice restored HPV-positive tumor clearance with cisplatin therapy. CONCLUSIONS: The HPV-positive tumors are not more curable based on increased epithelial sensitivity to cisplatin or radiation therapy. Instead, radiation and cisplatin induce an immune response to this antigenic cancer. The implications of these results may lead to novel therapies that enhance tumor eradication for HPV-positive cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“Radiation and oxaliplatin (a drug similar to cisplatin) have previously been shown to induce an immune response during therapy in experimentally tested models.(23) The HPV-positive tumors contain foreign viral proteins.”
BackgroundObeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474 · cited 1×
“For example, in an antigenic model of fibrosarcoma and colon carcinoma, radiation has been shown to cause calreticulin to transit to the cell surface.(24) The radiation-induced enhancement of calreticulin has been shown to be necessary to develop an antitumor response.”
BackgroundPhase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463 · cited 1×
“It has become increasingly clear for many cancers that the immune system has a critical role in response during therapy.(20,21) Although cisplatin is a known immunosuppressive agent, it does not suppress the function of the vaccine.”
Background
Cited by
Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer
Kimple, R. J., Smith, M. A., Blitzer, G. C., Torres, A. D., Martin, J. A., Yang, R. Z., Peet, C. R., Lorenz, L. D., Nickel, K. P., Klingelhutz, A. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0587 · Cited by 366
Chen, A. M., Felix, C., Wang, P.-C., Hsu, S., Basehart, V., Garst, J., Beron, P., Wong, D., Rosove, M. H., Rao, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30246-2 · Cited by 326
Rieckmann, T., Tribius, S., Grob, T. J., Meyer, F., Busch, C.-J., Petersen, C., Dikomey, E., & Kriegs, M. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.03.013 · Cited by 312
Concha-Benavente, F., Srivastava, R. M., Trivedi, S., Lei, Y., Chandran, U., Seethala, R. R., Freeman, G. J., & Ferris, R. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2001 · Cited by 304
Miyauchi, S., Sanders, P. D., Guram, K., Kim, S. S., Paolini, F., Venuti, A., Cohen, E. E. W., Gutkind, J. S., Califano, J. A., & Sharabi, A. B. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1771 · Cited by 64
Metadata
- Authors
- Spanos, W. C., Nowicki, P., Lee, D. W., Hoover, A., Hostager, B., Gupta, A., Anderson, M. E., & Lee, J. H.
- Venue
- Archives of Otolaryngology–Head & Neck Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2009-11-01
- Volume
- 135
- Issue
- 11
- Pages
- 1137
- ISSN
- 0886-4470 (ISSN-L)
- OpenAlex
- W2141859344
- Cited by
- 241
- References
- 3
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.